Analysts expect Healthequity Inc (NASDAQ:HQY) to report sales of $55.74 million for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Healthequity’s earnings, with the highest sales estimate coming in at $56.10 million and the lowest estimate coming in at $55.44 million. Healthequity reported sales of $44.19 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 26.1%. The firm is expected to report its next quarterly earnings report on Tuesday, September 5th.

According to Zacks, analysts expect that Healthequity will report full year sales of $55.74 million for the current fiscal year, with estimates ranging from $224.05 million to $225.36 million. For the next financial year, analysts expect that the company will post sales of $274.86 million per share, with estimates ranging from $267.39 million to $281.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Healthequity.

Healthequity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, June 6th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $55.40 million during the quarter, compared to analyst estimates of $54.77 million. Healthequity had a net margin of 25.31% and a return on equity of 20.36%. The business’s quarterly revenue was up 25.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.15 EPS.

A number of research firms recently weighed in on HQY. Cantor Fitzgerald raised their target price on shares of Healthequity from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Wednesday, June 7th. Chardan Capital raised their price target on Healthequity from $53.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, June 7th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $61.00 price target (up from $57.00) on shares of Healthequity in a research report on Monday, June 12th. J P Morgan Chase & Co raised their price target on Healthequity from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 22nd. Finally, Zacks Investment Research upgraded Healthequity from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research report on Wednesday, July 12th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $50.22.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/20/zacks-brokerages-expect-healthequity-inc-hqy-will-announce-quarterly-sales-of-55-74-million.html.

In other news, major shareholder Berkley Capital, Llc sold 4,002 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $51.99, for a total transaction of $208,063.98. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Stephen Neeleman sold 8,500 shares of the firm’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $50.83, for a total value of $432,055.00. Following the transaction, the insider now owns 1,000 shares in the company, valued at approximately $50,830. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,470,821 shares of company stock valued at $126,688,168. Corporate insiders own 29.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Peregrine Capital Management LLC raised its position in shares of Healthequity by 6.4% in the first quarter. Peregrine Capital Management LLC now owns 743,830 shares of the company’s stock valued at $29,776,000 after buying an additional 44,792 shares in the last quarter. New England Research & Management Inc. purchased a new position in shares of Healthequity during the first quarter valued at approximately $425,000. Highbridge Capital Management LLC purchased a new position in shares of Healthequity during the fourth quarter valued at approximately $1,003,000. Teachers Advisors LLC raised its position in shares of Healthequity by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 75,351 shares of the company’s stock valued at $3,053,000 after buying an additional 6,706 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Healthequity during the fourth quarter valued at approximately $14,203,000. Hedge funds and other institutional investors own 90.35% of the company’s stock.

Shares of Healthequity (NASDAQ HQY) traded down 1.9874% during midday trading on Thursday, hitting $47.3401. 317,632 shares of the stock were exchanged. The firm has a market cap of $2.84 billion, a PE ratio of 88.9851 and a beta of 1.79. The firm’s 50-day moving average is $50.33 and its 200 day moving average is $45.90. Healthequity has a 52-week low of $27.45 and a 52-week high of $54.95.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.